Table 2.

Results of nine SNPs selected for validation of an association with more aggressive prostate cancer

				500 K GWAS					Validation Study
			Controls (N=100)	More Aggressive‡ (N=202)			Controls (N=1167)	More Aggressive‖ (N=527)			Less Aggressive (N=595)
SNP	Chr	Gene	MAF†	OR	95% CI	p§	MAF	OR	95% CI	p††	OR	95% CI	p††	Het p‡‡
rs3774315	3q26	TNFSF10	0.15	2.50	1.55 – 4.03	7.34×10−5	0.25	1.17	0.99 – 1.38	0.03	1.25	1.08 – 1.46	0.002	0.45
rs8015211	14q22	FBXO34	0.25	2.25	1.53 – 3.32	1.64×10−5	0.33	1.12	0.96 – 1.30	0.08	0.99	0.85 – 1.15	0.56	0.17
rs12433615	14q22		0.23	2.16	1.47 – 3.18	4.06×10−5	0.31	1.10	0.94 – 1.28	0.12	1.10	0.95 – 1.28	0.10	0.97
rs1188069	14q22		0.13	2.52	1.55 – 4.11	6.38×10−5	0.20	1.12	0.94 – 1.34	0.11	1.02	0.86 – 1.22	0.40	0.39
rs2341883	14q22		0.24	2.06	1.41 – 3.02	1.01×10−4	0.32	1.20	1.03 – 1.40	0.01	1.19	1.03 – 1.38	0.01	0.96
rs6497287	15q13	HERC2	0.01	8.92	2.10 – 37.9	5.20×10−5	0.06	1.46	1.10 – 1.94	0.004	1.17	0.88 – 1.56	0.14	0.17
rs11150069	16q23	WWOX	0.41	0.42	0.28 – 0.62	9.43×10−6	0.30	1.01	0.85 – 1.19	0.54	1.11	0.95 – 1.29	0.90	0.34
rs4628973	16q24		0.38	0.35	0.24 – 0.54	4.62×10−7	0.30	1.02	0.86 – 1.20	0.58	0.89	0.76 – 1.04	0.07	0.16
rs225061	Xp21	IL1RAPL1	0.28	0.59	0.44 – 0.81	9.71×10−4	0.22	0.95	0.73 – 1.23	0.34	0.81	0.63 – 1.05	0.06	0.32

^†Minor Allele Frequency;

^‡More aggressive: diagnostic PSA ≥50ng/mL, regional/distant stage, Gleason Score ≥7(4+3), recurrence/progression event and/or prostate cancer-specific death;

^§Two-sided p-value;

^‖More aggressive: diagnostic PSA ≥20ng/mL, regional/distant stage, Gleason score ≥7 (3+4), recurrence/progression event and/or prostate cancer-specific death;

^††One-sided p-value;

^‡‡Heterogeneity p-value for the difference in ORs for more vs. less aggressive prostate cancer.